What is the main purpose of the 2014 Long-Term Incentive Plan that was approved?

The 2014 Long-Term Incentive Plan is designed to provide Regeneron's executive officers and non-employee directors with equity-based compensation. This includes the ability to grant non-qualified stock options, incentive stock options, and restricted stock awards, which are intended to align the interests of management and directors with those of shareholders and incentivize long-term performance.

What were the results of the advisory vote on executive compensation?

The advisory vote on executive compensation was approved, meaning a majority of the votes cast were in favor. However, a significant portion of shareholders voted against the proposal, indicating potential concerns or disagreements regarding the disclosed executive compensation practices.

Are there any specific concerns raised by the voting results for the Long-Term Incentive Plan?

While the 2014 Long-Term Incentive Plan was approved by shareholders, a substantial number of votes were cast against it. This suggests that some shareholders may have had reservations about the details of the plan, its potential dilution effect, or the compensation levels it enables.

Who were the directors elected at the Annual Meeting?

The Class II directors elected to serve until the 2017 Annual Meeting were Alfred G. Gilman, M.D., Ph.D., Joseph L. Goldstein, M.D., Christine A. Poon, and P. Roy Vagelos, M.D. The Class I director elected to serve until the 2016 Annual Meeting was Robert A. Ingram.

REGN 8-K: Leadership Changes & Shareholder Matters

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 18, 2014, detailing the outcomes of its 2014 Annual Meeting of Shareholders held on June 13, 2014. The most significant development for investors is the shareholder approval of the Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. This plan, previously adopted by the Board of Directors, allows for the issuance of various equity awards, including non-qualified stock options, incentive stock options, and restricted stock, to executive officers and non-employee directors. The filing also provides voting results for director elections, the ratification of PricewaterhouseCoopers LLP as the independent auditor, and an advisory vote on executive compensation. While the directors were overwhelmingly elected and the auditor ratification passed with strong support, the advisory vote on executive compensation received a mixed response, with a notable percentage of 'Against' votes. The approval of the new Long-Term Incentive Plan also saw a significant number of 'Against' votes, indicating some shareholder concern or disagreement with the specific terms or scope of the plan.

Key Highlights

1Shareholder approval of the 2014 Long-Term Incentive Plan, allowing for future equity-based compensation for executives and directors.
2Election of Class II directors Alfred G. Gilman, M.D., Ph.D., Joseph L. Goldstein, M.D., Christine A. Poon, and P. Roy Vagelos, M.D. to serve until 2017.
3Election of Class I director Robert A. Ingram to serve until 2016.
4Ratification of PricewaterhouseCoopers LLP as Regeneron's independent registered public accounting firm for the fiscal year ending December 31, 2014, with strong shareholder support.
5An advisory vote on executive compensation was approved, but with a notable percentage of shareholders voting against it.
6The 2014 Long-Term Incentive Plan, while approved, also received a significant number of 'Against' votes from shareholders.
7Filing includes forms of award agreements for stock options and restricted stock as exhibits.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Jun 18, 2014)

Summary

Key Highlights

Frequently Asked Questions